China Biotech Services (08037) announced interim results. Profit attributable to shareholders of HK$18.23 million turned a year-on-year loss into a profit

According to the Zhitong Finance App, China Biotech Service (08037) announced interim results for the six months ended June 30, 2026. The group obtained revenue of HK$37.226 million, an increase of 49.71%; profit attributable to the owners of the Company was HK$18.23 million, which turned a year-on-year loss into a profit; and a profit of HK$0.03 per share.

According to the announcement, the increase in revenue was mainly driven by the commencement of trial operation of the Pengbo (Hainan) Boron Neutron Capture Treatment Center in February 2026, and revenue from providing boron neutron capture treatment services of approximately HK$26.7 million.